Amylyx Pharmaceuticals Appoints New Board Member for 2025 Term

Amylyx Pharmaceuticals Inc (AMLX) has provided an announcement.

Amylyx Pharmaceuticals, Inc. has strengthened its Board of Directors by bringing on Bernhardt Zeiher, MD, as a Class I director, with his term extending to the 2025 annual stockholders’ meeting. His extensive industry experience includes a prominent tenure as Chief Medical Officer at Astellas Pharma and participation in several influential boards. Zeiher steps into a role on the Nominating and Corporate Governance Committee, succeeding Paul Fonteyne, and is set to receive a comprehensive compensation package including annual retainers and stock options under the company’s Non-Employee Director Compensation Policy.

See more data about AMLX stock on TipRanks’ Stock Analysis page.